Investors of MoonLake Immunotherapeutics Urged to Act on Claims Ahead of Deadline

Important Update for MoonLake Immunotherapeutics Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation concerning the potential claims on behalf of investors involved with MoonLake Immunotherapeutics (NASDAQ: MLTX). Investors who purchased or acquired shares between March 10, 2024, and September 29, 2025, are particularly encouraged to assess their legal options.

Contact Information
James (Josh) Wilson, a partner at Faruqi & Faruqi, is reaching out to investors who have suffered losses. Interested parties can contact him directly at 877-247-4292 or at 212-983-9330 (Ext. 1310) to discuss their rights and potential claims.

Background on the Investigation

This investigation is vital as it follows significant events affecting MoonLake's stock price, notably after the company's announcement on September 28, 2025. The firm disclosed disappointing results from its Phase 3 VELA program, revealing that the drug SLK did not demonstrate matches in effectiveness when compared to BIMZELX. Following this disclosure, shares plummeted by 89.9%, closing at just $6.24, a dramatic decline reflecting investor sentiment and trust.

Allegations Against MoonLake

The complaint against MoonLake asserts that the company and its executives misrepresented critical facts. Notably, they allegedly made false statements regarding the difference between Nanobodies and traditional monoclonal antibodies. Specific allegations include:
1. Both SLK and BIMZELX target similar inflammatory cytokines, namely IL-17A and IL-17F.
2. The distinct Nanobody structure of SLK did not provide superior clinical benefits over BIMZELX.
3. The presumed superior tissue penetration of SLK did not translate into effective results.
4. Defendants lacked a factual basis for positing SLK's superiority to monoclonal antibodies, leading to misinformed investor expectations.

Investor Rights and Legal Actions

As the investigation progresses, the firm advises potential lead plaintiffs to step forward. The lead plaintiff is determined to be the investor with the largest financial interest in the current claims. This individual will guide the litigation on behalf of the broader class of affected investors. If investors choose not to become lead plaintiffs, their chances of sharing in any potential recovery remain unaffected.

Faruqi & Faruqi also urging anyone with insights into MoonLake's actions to reach out, whether they be whistleblowers, former employees, shareholders, or others knowledgeable of the situation.

For further details on the ongoing class action lawsuit against MoonLake Immunotherapeutics, individuals can visit Faruqi & Faruqi’s website or contact partner Josh Wilson using the aforementioned phone numbers.

Stay connected with Faruqi & Faruqi on LinkedIn, X, and Facebook for the latest updates and information surrounding this case.

Conclusion
The deadline to request lead plaintiff status is December 15, 2025. Thus, affected investors should act promptly to ensure their voices are heard in this ongoing legal matter. Faruqi & Faruqi, LLP remains committed to advocating for investors' rights and seeks to navigate the complexities of this case diligently.